We publish our pricing. £1,500 a month per molecule. See it here →
Sample · Apixaban, England, May 2026

The monthly briefing, in full.

This is what a subscriber gets in their inbox on the first working day of every month. No teaser, no email wall, no "book a demo to see the rest". The whole thing.

01 · Headline

Primary-care items up 12.4% year on year.

Apixaban continues its steady march up the anticoagulant table. May 2026 primary care items sit at 1.42m, against 1.26m in May 2025. Hospital dispensing is up 6.9% on the same window.

The regional picture is quieter than the national one: Greater Manchester and North East & North Cumbria are pulling the average up; Cheshire & Merseyside is the only ICB in genuine decline this month.

02 · The chart of the month

Primary vs secondary care, indexed to Jan 2024.

Apixaban, England: primary vs secondary care
Volume per month, indexed, Jan 2024 = 100
16014012010080 Jan 24 Mar 25 May 26 Primary Hospital
Source: NHSBSA English Prescribing Data & SCMD, to May 2026 · dosetrend.com
03 · By Integrated Care Board

Top and bottom this month.

ICB Items, May 2026 Change YoY Spend
Greater Manchester 128,450 +12.4% £214,900
North East and North Cumbria 117,220 +8.1% £196,340
West Yorkshire 104,880 +7.6% £176,220
Cheshire and Merseyside 96,010 −3.2% £161,750
Kent and Medway 62,340 +2.1% £104,880

Source: NHSBSA EPD, May 2026. Full 42-ICB table in the subscriber dashboard.

04 · What to watch next month

Two things, no more.

Cheshire & Merseyside. Three months of decline is a pattern. The local formulary decision from March is starting to bite; watch whether it spreads to neighbouring ICBs.

Hospital dispensing gap. Primary care is running seven points ahead of secondary. That gap has closed after the summer for three years running; we'll flag if it doesn't this year.

Every molecule, every month

Your molecule, in your inbox, on the first.

Apply for access See pricing